Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 10/20 | 0.52 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882230 | 0.81 | VNN1 (0.53) | VNN1MAP3K12CDK1CDK2GRM5 | |
| SCHEMBL2882904 | 0.78 | IKBKB (0.57) | VNN1CDK1CDK2L3MBTL3 | |
| SCHEMBL15317646 | 0.75 | L3MBTL3 (0.66) | VNN1MCHR1ALDH1A1HPGDL3MBTL3 | |
| SCHEMBL17886764 | 0.75 | L3MBTL3 (0.66) | VNN1MCHR1ALDH1A1HPGDL3MBTL3 | |
| SCHEMBL5909079 | 0.75 | L3MBTL3 (0.55) | VNN1MCHR1L3MBTL3PDK2 | |
| SCHEMBL24185235 | 0.71 | L3MBTL3 (0.71) | MCHR1POLBHPGDL3MBTL3PDK2 | |
| SCHEMBL12237840 | 0.71 | L3MBTL3 (0.71) | ALDH1A1HPGDL3MBTL3PDK2 | |
| SCHEMBL5909215 | 0.71 | L3MBTL3 (0.67) | MCHR1KDM4EPOLBL3MBTL3PDK2 | |
| SCHEMBL6202647 | 0.71 | L3MBTL3 (0.67) | MCHR1KDM4EPOLBL3MBTL3PDK2 | |
| SCHEMBL10195734 | 0.71 | L3MBTL3 (0.71) | ALDH1A1HPGDL3MBTL3PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027086-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | Wyeth (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007136668-A2 | N-BENZOYL-AND N-BENZYLPYRROLIDIN-3-YLAMINES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2007-11-29 | — | — | WO | claimed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | claimed |
| US-7842715-B2 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270440-A1 | N-benzoyl- and N-benzylpyrrolidin-3-ylamines as histamine-3 antagonists | HRH4, HRH3, HRH2 | VNN1 1225/4885MAP3K12 1027/4885CDK1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.